UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000030077 |
|---|---|
| Receipt number | R000034327 |
| Scientific Title | Phase II study investigating efficacy and safety of TFTD plus bevacizumab by RAS mutation status in patients with unresectable advanced or recurrent colorectal cancer refractory or intolerant to standard chemotherapy |
| Date of disclosure of the study information | 2018/01/09 |
| Last modified on | 2021/07/12 14:26:08 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/11/22 11:48:08 | ||
| 2 | Update | 2018/01/09 09:09:17 | Recruitment status |
|
| 3 | Update | 2018/09/20 13:11:25 | Recruitment status |
|
| 4 | Update | 2021/07/09 15:07:18 | Recruitment status Date of IRB Anticipated trial start date Last follow-up date |
|
| 5 | Update | 2021/07/12 13:39:09 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
| 6 | Update | 2021/07/12 14:26:08 | Publication of results URL related to results and publications Number of participants that the trial has enrolled Results |
